Clinical Trial Update: PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-00299804 as a single agent in advanced non-small cell lung cancer after failing chemotherapy and erlotinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PF-00299804

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non Small Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2019-05-21